VIR

Vir Biotechnology, Inc.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

VIRVir Biotechnology, Inc.
0Calm
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
Signing up patientsPhase 1/2645 patientsMain results: Apr 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

4 sales (0 not pre-planned) · 0 purchases

de Verneuil VaninaEVP, General Counsel, Corp Sec · Nov 3, 2026Sold 2,407 sharesabout $27 thousand · pre-planned
de Verneuil VaninaEVP, General Counsel, Corp Sec · Nov 2, 2026Sold 1,343 sharesabout $15 thousand · pre-planned
Napolitano JanetBoard member · Jun 1, 2026Sold 3,200 sharesabout $30 thousand · pre-planned
Sabatini BrentSVP, Chief Accounting Officer · Jun 1, 2026Sold 379 sharesabout $4 thousand · pre-planned

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.

VIR